Core Viewpoint - Guangdong Dongyangguang Pharmaceutical Co., Ltd. officially listed on the Hong Kong Stock Exchange on August 7, 2023, highlighting its growth and significance in the pharmaceutical industry [2]. Group 1: Laboratory Overview - The National Key Laboratory for Antibacterial Drug Research, known for its "liquid phase forest," was approved for construction by the Ministry of Science and Technology in September 2015 and was officially recognized in 2023 [3][4]. - The laboratory features a 50,000 square meter experimental space equipped with over 400 high-performance liquid chromatography instruments, 20 liquid chromatography-mass spectrometry instruments, and various other advanced analytical devices [4][11]. Group 2: Research Achievements - The laboratory has ranked first in China for patent applications and authorizations from 2014 to 2023, with a total of 2,403 invention patents filed and 1,351 granted [5]. - The current research focuses on the pathogenic mechanisms of persistent viruses, new drug development for sudden viral outbreaks like COVID-19, antibiotic resistance mechanisms, and complications from infectious diseases [7]. Group 3: Laboratory Design and Safety - The "liquid phase forest" employs a "human-machine separation" design, which significantly reduces the exposure of researchers to organic solvents, demonstrating a commitment to safety and well-being in the laboratory environment [11].